Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

LABAs effective in COPD

Use of Long-acting ?2-agonists reduces severe exacerbations in patients with COPD, with no adverse impact on all-cause or respiratory mortality, a meta-analysis shows.

A team of international researchers assessed a total of 27 studies.

LABA treatment reduced severe exacerbations by 22% compared with placebo, although it was associated with significantly more severe exacerbations than tiotropium in moderate to severe disease.

Use of the drugs with inhaled steroids reduced the risk of respiratory death compared with LABAs alone.

Chest. 2008; 133:1079-108

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say